NCT06006923
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06006923
Title Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Anwaar Saeed
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope NOT_YET_RECRUITING Irvine California 92618 United States Details
AdventHealth Orlando RECRUITING Orlando Florida 32804 United States Details
University of Illinois Cancer Center RECRUITING Chicago Illinois 60612 United States Details
University of Michigan NOT_YET_RECRUITING Ann Arbor Michigan 48109 United States Details
UPMC Hillman Cancer Center RECRUITING Pittsburgh Pennsylvania 15232 United States Details
Fred Hutchinson Cancer Research Center RECRUITING Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field